Bayer to pull follicular lymphoma drug Aliqopa from US market in another blow to PI3K inhibitor space

Bay­er said it will vol­un­tar­i­ly with­draw its fol­lic­u­lar lym­phoma drug Aliqopa from the US af­ter a con­fir­ma­to­ry tri­al dis­ap­point­ment, mark­ing the third PI3K in­hibitor to be pulled in re­cent years.

A Bay­er spokesper­son told End­points News in an email that the Phase III CHRONOS-4 tri­al of Aliqopa plus stan­dard im­munother­a­py in pa­tients with re­lapsed in­do­lent non-Hodgkin lym­phoma did not meet its pri­ma­ry end­point, which is list­ed as pro­gres­sion-free sur­vival on Clin­i­cal­Tri­als.gov. Topline da­ta from the con­fir­ma­to­ry study are yet to be pub­lished.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.